Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study

BACKGROUND: The 2-drug regimen dolutegravir (DTG) + lamivudine (3TC) is indicated for treatment-naive adults with human immunodeficiency virus type 1 (HIV-1). We present efficacy and safety of switching to DTG/3TC in virologically suppressed individuals. METHODS: TANGO is an open-label, multicenter,...

Descripción completa

Detalles Bibliográficos
Autores principales: van Wyk, Jean, Ajana, Faïza, Bisshop, Fiona, De Wit, Stéphane, Osiyemi, Olayemi, Portilla Sogorb, Joaquín, Routy, Jean-Pierre, Wyen, Christoph, Ait-Khaled, Mounir, Nascimento, Maria Claudia, Pappa, Keith A, Wang, Ruolan, Wright, Jonathan, Tenorio, Allan R, Wynne, Brian, Aboud, Michael, Gartland, Martin J, Smith, Kimberly Y
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Articles and Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643745/
https://www.ncbi.nlm.nih.gov/pubmed/31905383
http://dx.doi.org/10.1093/cid/ciz1243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643745/
https://www.ncbi.nlm.nih.gov/pubmed/31905383
http://dx.doi.org/10.1093/cid/ciz1243

Ejemplares similares